Press Release Dec 01 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Topiramate Extended-Release Capsules. The capsules are indicated for preventing seizures in epilepsy and may also help prevent migraines. The drug will be manufactured at the company's facility in Ahmedabad SEZ, India.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Nov 28 2022
- Press Release Nov 23 2022
- Press Release Nov 16 2022
- Press Release Nov 08 2022
- Press Release Nov 07 2022
Later from Zydus Lifesciences
- Press Release Dec 02 2022
- Press Release Dec 10 2022
- Press Release Dec 22 2022
- Loss of Share Certificates
- Press Release Dec 30 2022
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences